lutetium Lu 177 PSMA-10.1

{
  "id": "MLC-T-ONC-014922",
  "term": "lutetium Lu 177 PSMA-10.1",
  "field": "Oncology and biomedicine",
  "definition": "A radioconjugate composed of PSMA-10.1, a prostate-specific membrane antigen (PSMA)-targeting ligand and radiolabeled with the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 PSMA-10.1, PSMA-10.1 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors.",
  "synonyms": [
    "(177Lu) rhPSMA-10.1",
    "177Lu rhPSMA-10.1",
    "177Lu radiohybrid PSMA-10.1",
    "177Lu-rhPSMA-10.1"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-psma-10-1/"
}